Zeng Minyan, Zhen Juanying, Zheng Xiaodan, Qiu Hongyan, Xu Xiaonan, Wu Jun, Lin Zhijian, Hu Jun
Department of Neurology, Peking University Shenzhen Hospital, Shenzhen, China.
Department of Clinical Medicine, Shantou University Medical College, Shantou, China.
Front Neurol. 2020 Oct 27;11:566124. doi: 10.3389/fneur.2020.566124. eCollection 2020.
Knowledge about the classic risk and protective factors of ischemic stroke is accumulating, but the underlying pathogenesis has not yet been fully understood. As emerging evidence indicates that DNA methylation plays a role in the pathological process of cerebral ischemia, this study aims to summarize the evidence of the association between DNA methylation and ischemic stroke. MEDLINE, EMBASE, PubMed, and Cochrane Central Register of Controlled Trials were searched for eligible studies. The results reported by each study were summarized narratively. A total of 20 studies with 7,014 individuals finally met the inclusion criteria. Three studies focused on global methylation, 11 studies on candidate-gene methylation, and six on epigenome-wide methylation analysis. Long-interspersed nuclear element 1 was found to be hypomethylated in stroke cases in two studies. Another 16 studies reported 37 genes that were differentially methylated between stroke cases and controls. Individuals with ischemic stroke were also reported to have higher acceleration in Hanuum 's epigenetic age compared to controls. DNA methylation might be associated with ischemic stroke and play a role in several pathological pathways. It is potentially a promising biomarker for stroke prevention, diagnosis and treatment, but the current evidence is limited by sample size and cross-sectional or retrospective design. Therefore, studies on large asymptomatic populations with the prospective design are needed to validate the current evidence, explore new pathways and identify novel risk/protective loci.
关于缺血性中风的经典风险和保护因素的知识正在不断积累,但潜在的发病机制尚未完全明确。由于新出现的证据表明DNA甲基化在脑缺血的病理过程中发挥作用,本研究旨在总结DNA甲基化与缺血性中风之间关联的证据。检索了MEDLINE、EMBASE、PubMed和Cochrane对照试验中央注册库,以查找符合条件的研究。对每项研究所报告的结果进行了叙述性总结。共有20项研究、7014名个体最终符合纳入标准。三项研究聚焦于全基因组甲基化,11项研究关注候选基因甲基化,六项研究进行了表观基因组范围的甲基化分析。两项研究发现中风病例中长散在核元件1发生低甲基化。另外16项研究报告了37个在中风病例和对照之间存在差异甲基化的基因。与对照组相比,缺血性中风患者的哈努姆表观遗传年龄加速也更高。DNA甲基化可能与缺血性中风相关,并在多种病理途径中发挥作用。它可能是中风预防、诊断和治疗的一个有前景的生物标志物,但目前的证据受样本量以及横断面或回顾性设计的限制。因此,需要对大量无症状人群进行前瞻性设计的研究,以验证当前证据、探索新途径并确定新的风险/保护位点。